{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:03:28Z","timestamp":1780117408749,"version":"3.54.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03557-9","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:11:52Z","timestamp":1774685512000},"page":"2458-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Past, Present, and Future of von Willebrand Disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Mary","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-8541","authenticated-orcid":false,"given":"Angela C.","family":"Weyand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"s5","key":"3557_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2008.01848.x","volume":"14","author":"AJ Reininger","year":"2008","unstructured":"Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(s5):11\u201326. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01848.x.","journal-title":"Haemophilia"},{"issue":"12","key":"3557_CR2","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/jth.12008","volume":"10","author":"PJ Lenting","year":"2012","unstructured":"Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428\u201337. https:\/\/doi.org\/10.1111\/jth.12008.","journal-title":"J Thromb Haemost"},{"key":"3557_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI106480","volume":"50","author":"TS Zimmerman","year":"1971","unstructured":"Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor\u00a0VIII deficiency) and von Willebrands disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor\u00a0V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971;50:244\u201354. https:\/\/doi.org\/10.1172\/JCI106480.","journal-title":"J Clin Invest"},{"issue":"4706","key":"3557_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1126\/science.3874428","volume":"228","author":"D Ginsburg","year":"1985","unstructured":"Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985;228(4706):1401\u20136. https:\/\/doi.org\/10.1126\/science.3874428.","journal-title":"Science"},{"key":"3557_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-023-00375-8","volume":"8","author":"O Seidizadeh","year":"2023","unstructured":"Seidizadeh O, Cairo A, Baronciani L, Valenti L, Peyvandi F. Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases. npj Genom Med. 2023;8:31. https:\/\/doi.org\/10.1038\/s41525-023-00375-8.","journal-title":"npj Genom Med"},{"key":"3557_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra040403","volume":"351","author":"PM Mannucci","year":"2004","unstructured":"Mannucci PM. Treatment of von Willebrand\u2019s disease. N Engl J Med. 2004;351:683\u201394. https:\/\/doi.org\/10.1056\/NEJMra040403.","journal-title":"N Engl J Med"},{"issue":"1","key":"3557_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","volume":"5","author":"PD James","year":"2021","unstructured":"James PD,\u00a0Connell NT, Ameer B\u00a0et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280\u2013300. https:\/\/doi.org\/10.1182\/bloodadvances.2020003265.","journal-title":"Blood Adv"},{"issue":"1","key":"3557_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","volume":"5","author":"NT Connell","year":"2021","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on management of von Willebrand disease. Blood Adv. 2021;5(1):301\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2020003264.","journal-title":"Blood Adv"},{"key":"3557_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/JBM.S389241","volume":"14","author":"P Du","year":"2023","unstructured":"Du P, Bergamasco A, Moride Y, Truong Berthoz F, \u00d6zen G, Tzivelekis S.\u00a0von Willebrand disease epidemiology, burden of illness and management: a systemic review. J Blood Med. 2023;14:189\u2013208. https:\/\/doi.org\/10.2147\/JBM.S389241.","journal-title":"J Blood Med"},{"issue":"8","key":"3557_CR10","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3324\/haematol.2025.287572","volume":"110","author":"A Gringeri","year":"2025","unstructured":"Gringeri A, Mannuccio Mannucci P, Gringeri M, Castaman G, Peyvandi F. Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A. Haematologica. 2025;110(8):1710\u201322. https:\/\/doi.org\/10.3324\/haematol.2025.287572.","journal-title":"Haematologica"},{"issue":"5","key":"3557_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/hae.13292","volume":"23","author":"RF Sidonio","year":"2017","unstructured":"Sidonio RF, Haley KM, Fallaize D. Impact of diagnosis of von Willebrand disease on patient outcomes: analysis of medical insurance claims data. Haemophilia. 2017;23(5):743\u20139. https:\/\/doi.org\/10.1111\/hae.13292.","journal-title":"Haemophilia"},{"issue":"8","key":"3557_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/1076029616675969","volume":"23","author":"A Swami","year":"2016","unstructured":"Swami A, Kaur V. von Willebrand disease: a concise review and update for the practicing physician. Clin Appl Thromb Hemost. 2016;23(8):900\u201310. https:\/\/doi.org\/10.1177\/1076029616675969.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"3557_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.hoc.2021.07.004","volume":"35","author":"AC Weyand","year":"2021","unstructured":"Weyand AC, Flood VH. von Willebrand disease: current status of diagnosis and management. Hematol Oncol Clin North Am. 2021;35(6):1085\u2013101. https:\/\/doi.org\/10.1016\/j.hoc.2021.07.004.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"3557_CR14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","volume":"8","author":"F Rodeghiero","year":"2010","unstructured":"Rodeghiero F, Tosetto A, Abshire T\u00a0et al. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proprosal for a new bleeding score for inherited bleeding disorders. J Thromb Haemostas. 2010;8(9):2063\u20135. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03975.x.","journal-title":"J Thromb Haemostas"},{"issue":"9","key":"3557_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/ajh.25869","volume":"95","author":"J Jaffray","year":"2020","unstructured":"Jaffray J, Staber JM, Malvar J et al. Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: a multi-center study. Am J Hematol. 2020;95(9):1022\u20139. https:\/\/doi.org\/10.1002\/ajh.25869.","journal-title":"Am J Hematol"},{"key":"3557_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.transci.2018.07.005","volume":"57","author":"ES Rao","year":"2018","unstructured":"Rao ES, Ng CJ. Current approaches to diagnostic testing in von Willebrand disease. Transfus Apher Sci. 2018;57:463\u20135. https:\/\/doi.org\/10.1016\/j.transci.2018.07.005.","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"3557_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.hoc.2019.01.010","volume":"33","author":"SH O\u2019Brien","year":"2019","unstructured":"O\u2019Brien SH, Saini S. von Willebrand disease in pediatrics. Hematol Oncol Clin North Am. 2019;33(3):425\u201338. https:\/\/doi.org\/10.1016\/j.hoc.2019.01.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3557_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/jth.13243","volume":"14","author":"A De Jong","year":"2016","unstructured":"De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost. 2016;14:449\u201360. https:\/\/doi.org\/10.1111\/jth.13243.","journal-title":"J Thromb Haemost"},{"key":"3557_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.blre.2016.08.003","volume":"31","author":"LL Swystun","year":"2017","unstructured":"Swystun LL, James PD. Genetic diagnosis in hemophilia and von Willebrand disease. Blood Rev. 2017;31:47\u201356. https:\/\/doi.org\/10.1016\/j.blre.2016.08.003.","journal-title":"Blood Rev"},{"issue":"11","key":"3557_CR20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/jth.141","volume":"17","author":"BS Doshi","year":"2019","unstructured":"Doshi BS, Rogers RS, Whitworth HB\u00a0et al. Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients. J Thromb Haemost. 2019;17(11):1838\u201347. https:\/\/doi.org\/10.1111\/jth.141.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3557_CR21","doi-asserted-by":"publisher","first-page":"E439","DOI":"10.1002\/ajh.26343","volume":"96","author":"AC Weyand","year":"2021","unstructured":"Weyand AC, Kouides P, Malvar J, Jaffray J. Is \u2265 100% the magic number to rule out the laboratory diagnosis of von Willebrand disease based on initial testing? Am J Hematol. 2021;96(11):E439\u201341. https:\/\/doi.org\/10.1002\/ajh.26343.","journal-title":"Am J Hematol"},{"issue":"4","key":"3557_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12513","volume":"5","author":"MC Brown","year":"2021","unstructured":"Brown MC, White MH, Friedberg R et al. Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease. Res Pract Thromb Haemost. 2021;5(4):e12513. https:\/\/doi.org\/10.1002\/rth2.12513.","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"3557_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/bloodadvances.2023011910","volume":"8","author":"J Simoneau","year":"2024","unstructured":"Simoneau J, Tay C, Wheeler A et al. Association between hemoglobin values and VWF assays: a multicenter investigation. Blood Adv. 2024;8(5):1152\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2023011910.","journal-title":"Blood Adv"},{"key":"3557_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/JBM.S232758","volume":"12","author":"G Castaman","year":"2021","unstructured":"Castaman G, Linari S. Obstacles to early diagnosis and treatment of inherited von Willebrand disease: current perspectives. J Blood Med. 2021;12:165\u201375. https:\/\/doi.org\/10.2147\/JBM.S232758.","journal-title":"J Blood Med"},{"key":"3557_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000391","author":"H Vander Meulen","year":"2022","unstructured":"VanderMeulen H, Arya S, Nersesian S, Philbert N, Sholzberg M. What have we learned about the patient\u2019s experience of von Willebrand disease? A focus on women. Hematol Am Soc Hematol Educ Program. 2022. https:\/\/doi.org\/10.1182\/hematology.2022000391.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"3557_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474086.2023.2243386","volume":"16","author":"GH Tang","year":"2023","unstructured":"Tang GH, Thachil J, Bowman M, Bekdache C, James PD, Sholzberg M.\u00a0Patient-centered care in von Willebrand disease: are we there yet? Expert Rev Hematol. 2023;16(9):641\u20139. https:\/\/doi.org\/10.1080\/17474086.2023.2243386.","journal-title":"Expert Rev Hematol"},{"key":"3557_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.11.042","author":"MY Abou-Ismail","year":"2023","unstructured":"Abou-Ismail MY, James PD, Flood VH, Connell NT. Beyond the guidelines: how we approach challenging scenarios in the diagnosis and management of von Willebrand disease. J Thromb Haemostas. 2023. https:\/\/doi.org\/10.1016\/j.jtha.2022.11.042.","journal-title":"J Thromb Haemostas"},{"issue":"6","key":"3557_CR28","first-page":"427","volume":"38","author":"S Sindet-Pedersen","year":"1991","unstructured":"Sindet-Pedersen S. Haemostasis in oral surgery-the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system. Dan Med Bull. 1991;38(6):427\u201343.","journal-title":"Dan Med Bull"},{"issue":"1","key":"3557_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1182\/blood-2024-206074","volume":"144","author":"A Vagrecha","year":"2024","unstructured":"Vagrecha A, Stancho J, Origho M, Martinez L, Acharya S. Use of low dose tranexamic acid in patients with bleeding disorders. Blood. 2024;144(1):1223. https:\/\/doi.org\/10.1182\/blood-2024-206074.","journal-title":"Blood"},{"issue":"3","key":"3557_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/ndt\/14.3.750","volume":"14","author":"JR Koo","year":"1999","unstructured":"Koo JR, Lee YK, Kim YS, Cho WY, Kim HK, Won NH.\u00a0Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid). Nephrol Dial Transpl. 1999;14(3):750\u20132. https:\/\/doi.org\/10.1093\/ndt\/14.3.750.","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"3557_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070967","volume":"15","author":"B Reardon","year":"2025","unstructured":"Reardon B, Pasalic L, Favaloro EJ. A review of desmopressin use in bleeding disorders: an unsung hero? Biomolecules. 2025;15(7):967. https:\/\/doi.org\/10.3390\/biom15070967.","journal-title":"Biomolecules"},{"key":"3557_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","volume":"82","author":"PM Mannucci","year":"1992","unstructured":"Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82:87\u201393. https:\/\/doi.org\/10.1111\/j.1365-2141.1992.tb04598.x.","journal-title":"Br J Haematol"},{"key":"3557_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/01.mph.0000168728.49519.4a","volume":"27","author":"P Das","year":"2005","unstructured":"Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol. 2005;27:330\u20132. https:\/\/doi.org\/10.1097\/01.mph.0000168728.49519.4a.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"3557_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","volume":"14","author":"WL Nichols","year":"2008","unstructured":"Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia. 2008;14(2):171\u2013232. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01643.x.","journal-title":"Haemophilia"},{"issue":"2","key":"3557_CR35","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.2450\/2011.003S","volume":"2","author":"G Castaman","year":"2011","unstructured":"Castaman G. Treatment of von Willebrand disease with FVIII\/VWF concentrates. Blood Transfus. 2011;2(2):s9-13. https:\/\/doi.org\/10.2450\/2011.003S.","journal-title":"Blood Transfus"},{"issue":"1","key":"3557_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1076029606296399","volume":"13","author":"JJ Michiels","year":"2007","unstructured":"Michiels JJ, van Vliet HH, Berneman Z et al. Intravenous DDAVP and factor\u00a0VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleeding in patients with von Willebrand disease type\u00a01, 2 and 3. Clin Appl Thromb Hemost. 2007;13(1):14\u201334. https:\/\/doi.org\/10.1177\/1076029606296399.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"17","key":"3557_CR37","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","volume":"126","author":"JC Gill","year":"2015","unstructured":"Gill JC, Castaman G, Windyga J et al.\u00a0Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038\u201346. https:\/\/doi.org\/10.1182\/blood-2015-02-629873.","journal-title":"Blood"},{"issue":"5","key":"3557_CR38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","volume":"122","author":"PD James","year":"2013","unstructured":"James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122(5):636\u201340. https:\/\/doi.org\/10.1182\/blood-2012-10-462085.","journal-title":"Blood"},{"issue":"18","key":"3557_CR39","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","volume":"3","author":"AC Weyand","year":"2019","unstructured":"Weyand AC, Flood VH, Shavit JA, Pipe SW. Efficacy of emicizumab in a pediatric patient with type\u00a03 von Willebrand disease and alloantibodies. Blood Adv. 2019;3(18):2748\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2019000656.","journal-title":"Blood Adv"},{"issue":"3","key":"3557_CR40","first-page":"387","volume":"88","author":"M Makris","year":"2002","unstructured":"Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease. Thromb Haemost. 2002;88(3):387\u20138.","journal-title":"Thromb Haemost"},{"issue":"3","key":"3557_CR41","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/hae.13436","volume":"24","author":"AC Weyand","year":"2018","unstructured":"Weyand AC, Jesudas R, Pipe SW. Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome. Haemophilia. 2018;24(3):e120\u20131. https:\/\/doi.org\/10.1111\/hae.13436.","journal-title":"Haemophilia"},{"issue":"3","key":"3557_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/hae.13436","volume":"24","author":"AC Weyand","year":"2018","unstructured":"Weyand AC, Jesudas R, Pipe SW. Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome. Haemophilia. 2018;24(3):329\u2013504. https:\/\/doi.org\/10.1111\/hae.13436.","journal-title":"Haemophilia"},{"key":"3557_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/20406207261419941","author":"Z Hua","year":"2026","unstructured":"Hua Z, Miao W, Zhang P, et al. Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application. Ther Adv Hematol. 2026. https:\/\/doi.org\/10.1177\/20406207261419941.","journal-title":"Ther Adv Hematol"},{"key":"3557_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/hae.12841","volume":"22","author":"K Livesey","year":"2016","unstructured":"Livesey K, Yealy DM, Li J, Moore CG, Ragni MV. von Willebrand disease in the emergency department. Haemophilia. 2016;22:263\u20137. https:\/\/doi.org\/10.1111\/hae.12841.","journal-title":"Haemophilia"},{"issue":"6","key":"3557_CR45","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.4317\/jced.62620","volume":"17","author":"G Ascani","year":"2025","unstructured":"Ascani G, Ranalli P, Azzuni F, Benfatto S, Romano M, Di Nobile E. Managing oral surgery in von Willebrand disease: lessons from a challenging case. J Clin Exp Dent. 2025;17(6):e742\u20135. https:\/\/doi.org\/10.4317\/jced.62620.","journal-title":"J Clin Exp Dent"},{"key":"3557_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2025.103936","author":"LC Porfirio de Sousa","year":"2025","unstructured":"Sousa LCP, F\u00e9lix ECGDC, Hespanhol W, Pinheiro RDS. Oral post-surgical complications in patients with hemophilia and von Willebrand disease. Hematol Transfus Cell Ther. 2025. https:\/\/doi.org\/10.1016\/j.htct.2025.103936.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3 Pt 2","key":"3557_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/s0002-9378(96)80086-x","volume":"175","author":"CJ Chuong","year":"1996","unstructured":"Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol. 1996;175(3 Pt 2):787\u201392. https:\/\/doi.org\/10.1016\/s0002-9378(96)80086-x.","journal-title":"Am J Obstet Gynecol"},{"key":"3557_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/JBM.S9890","volume":"2","author":"E Tuohy","year":"2011","unstructured":"Tuohy E, Litt E, Alikhan R. Treatment of patients with von Willebrand disease. J Blood Med. 2011;2:49\u201357. https:\/\/doi.org\/10.2147\/JBM.S9890.","journal-title":"J Blood Med"},{"key":"3557_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100119","author":"S Kuthiala","year":"2023","unstructured":"Kuthiala S, Grabell J, Relke N\u00a0et al. Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center. Res Pract Thromb Haemost. 2023. https:\/\/doi.org\/10.1016\/j.rpth.2023.100119.","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"3557_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1365-2141.2009.07610.x","volume":"145","author":"PA Kouides","year":"2009","unstructured":"Kouides PA, Byams VR, Philipp CS et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212\u201320. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07610.x.","journal-title":"Br J Haematol"},{"key":"3557_CR51","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000443393","volume":"81","author":"M Kiseli","year":"2016","unstructured":"Kiseli M, Kayikcioglu F, Evliyaoglu O, Haberal A. Comparison of therapeutic efficacies of norethistrone, tranexamic acid and levonorgestrel-releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecol Obstet Invest. 2016;81:447\u201353. https:\/\/doi.org\/10.1159\/000443393.","journal-title":"Gynecol Obstet Invest"},{"issue":"14","key":"3557_CR52","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","volume":"2","author":"M Lavin","year":"2018","unstructured":"Lavin M, Aguila S, Dalton N et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2(14):1784\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2018017418.","journal-title":"Blood Adv"},{"issue":"3","key":"3557_CR53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/hae.14550","volume":"28","author":"A El Alayli","year":"2022","unstructured":"El Alayli A, Brignardello Petersen R, Husainat NM\u00a0et al. Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: a systematic literature review. Haemophilia. 2022;28(3):373\u201387. https:\/\/doi.org\/10.1111\/hae.14550.","journal-title":"Haemophilia"},{"issue":"5","key":"3557_CR54","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2450\/2019.0183-18","volume":"17","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Castaman G, Gresele P\u00a0et al. A phase\u00a0III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17(5):391\u20138. https:\/\/doi.org\/10.2450\/2019.0183-18.","journal-title":"Blood Transfus"},{"issue":"Suppl 1","key":"3557_CR55","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","volume":"16","author":"E Berntorp","year":"2005","unstructured":"Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(Suppl 1):S23-26. https:\/\/doi.org\/10.1097\/01.mbc.0000167659.23262.18.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"3557_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","volume":"15","author":"E Berntorp","year":"2009","unstructured":"Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease-effiacy and safety of Wilate, a new generation von Willebrand factor\/factor\u00a0VIII concentrate. Haemophilia. 2009;15(1):122\u201330. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01901.x.","journal-title":"Haemophilia"},{"issue":"6","key":"3557_CR57","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","volume":"5","author":"A Borel-Derlon","year":"2007","unstructured":"Borel-Derlon A, Federici AB, Roussel-Robert V\u00a0et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5(6):1115\u201324. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02562.x.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3557_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","volume":"16","author":"AM Federici","year":"2010","unstructured":"Federici AB, Barillari G, Zanon E et al. Efficacy and safety of highly purified, doubly virus-inactivated vWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010;16(1):101\u201310. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02088.x.","journal-title":"Haemophilia"},{"issue":"4","key":"3557_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/mbc.0000000000000257","volume":"26","author":"E Holm","year":"2015","unstructured":"Holm E, Abshire TC, Bowen J et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand disease prophylaxis network. Blood Coagul Fibrinolysis. 2015;26(4):383\u20138. https:\/\/doi.org\/10.1097\/mbc.0000000000000257.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"S1","key":"3557_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/blood-2025-307","volume":"146","author":"N Ayad","year":"2025","unstructured":"Ayad N, Al-Samkari H. Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von Willebrand disease and acquired von Willebrand syndrome. Blood. 2025;146(S1):307. https:\/\/doi.org\/10.1182\/blood-2025-307.","journal-title":"Blood"},{"issue":"3","key":"3557_CR61","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377","volume":"10","author":"C Negrier","year":"2023","unstructured":"N\u00e9grier C, Mahlangu J, Lehle M\u00a0et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single arm, phase\u00a03 study. Haematology. 2023;10(3):e168\u201377. https:\/\/doi.org\/10.1016\/S2352-3026(22)00377.","journal-title":"Haematology"},{"key":"3557_CR62","unstructured":"US National Library of Medicine. ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05500807. Accessed 15 Jan 2026."},{"issue":"2","key":"3557_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/hae.14491","volume":"28","author":"C Shanmukhaiah","year":"2022","unstructured":"Shanmukhaiah C, Jijina F, Kannan S\u00a0et al. Efficacy of emicizumab in von Willebrand disease (vWD) patients with and without alloantibodies to von Willebrand factor (vWF): report of two cases and review of literature. Haemophilia. 2022;28(2):286\u201391. https:\/\/doi.org\/10.1111\/hae.14491.","journal-title":"Haemophilia"},{"issue":"S1","key":"3557_CR64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208020","volume":"144","author":"CM Millar","year":"2024","unstructured":"Millar CM, Raheja P, Wheeler AP et al. A phase\u00a0Ia study of VGA039, a protein S-targeting monoclonal antibody, in individuals with von Willebrand disease demonstrates concentration-dependent increases in thrombin generation for reducing bleeding. Blood. 2024;144(S1):3981.","journal-title":"Blood"},{"key":"3557_CR65","unstructured":"US National Library of Medicine. ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05776069. Accessed 15 Jan 2026."},{"issue":"10","key":"3557_CR66","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2022016571","volume":"141","author":"CA Katarina","year":"2023","unstructured":"Ay C, Kovacevic K, Kraemmer D et al. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. Blood. 2023;141(10):1147\u201358. https:\/\/doi.org\/10.1182\/blood.2022016571.","journal-title":"Blood"},{"issue":"18","key":"3557_CR67","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","volume":"6","author":"C Ay","year":"2022","unstructured":"Ay C, Pabinger I, Kovacevic KD et al. The vWF binding aptamer rondoraptivon pegol increases platelet counts and vWF\/FVIII in type\u00a02B von Willebrand disease. Blood Adv. 2022;6(18):5467\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2022007805.","journal-title":"Blood Adv"},{"issue":"S1","key":"3557_CR68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202611","volume":"144","author":"M Moser","year":"2024","unstructured":"Moser M, Ay C, Schoergenhofer C et al. Rondaptivon pegol (BT200) to correct thrombocytopenia in a peri-interventional setting in type\u00a02B von Willebrand disease (vWD). Blood. 2024;144(S1):3984.","journal-title":"Blood"},{"key":"3557_CR69","unstructured":"US National Library of Medicine. ClinicalTrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT04677803. Accessed 15 Jan 2026."},{"issue":"02","key":"3557_CR70","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1160\/TH11-12-0889","volume":"108","author":"P Jilma-Stohlawetz","year":"2012","unstructured":"Jilma-Stohlawetz P, Kn\u00f6bl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type\u00a02B von Willebrand disease. Thromb Haemost. 2012;108(02):284\u201390. https:\/\/doi.org\/10.1160\/TH11-12-0889.","journal-title":"Thromb Haemost"},{"issue":"21","key":"3557_CR71","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood.2025029401","volume":"146","author":"I Peyron","year":"2025","unstructured":"Peyron I, Casari C, McCluskey G\u00a0et al. A bispecific nanobody for the treatment of von Willebrand disease type\u00a01. Blood. 2025;146(21):2597\u2013607. https:\/\/doi.org\/10.1182\/blood.2025029401.","journal-title":"Blood"},{"issue":"24","key":"3557_CR72","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1182\/bloodadvances.2023010716","volume":"7","author":"C Casari","year":"2023","unstructured":"Casari C, Leung J, James PD. New and emerging therapies for women, girls, and people with the potential to menstruate with vWD. Blood Adv. 2023;7(24):7501\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2023010716.","journal-title":"Blood Adv"},{"issue":"S1","key":"3557_CR73","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2023-187279","volume":"142","author":"S Sivapalaratnam","year":"2023","unstructured":"Sivapalaratnam S, Austin S, Lorch U et al. A phase\u00a01\/2, first-in-human, study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-001 in participants with Glanzmann thrombasthenia. Blood. 2023;142(S1):1225. https:\/\/doi.org\/10.1182\/blood-2023-187279.","journal-title":"Blood"},{"key":"3557_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1182\/blood-2025-842","volume":"146","author":"P Saultier","year":"2025","unstructured":"Saultier P, Sivapalaratnam S, Xavier F et al. Sutacimig, a novel bispecific antibody for prophylactic treatment of Glanzmann thrombasthenia: analysis of a phase\u00a02 study. Blood. 2025;146:842\u20133.","journal-title":"Blood"},{"issue":"S1","key":"3557_CR75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-8230","volume":"146","author":"P Raheja","year":"2025","unstructured":"Raheja P, Knott A, Lowe G et al. Velora pioneer, phase\u00a01\/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 for prophylaxis in von Willebrand disease: a trial in progress. Blood. 2025;146(S1):8230. https:\/\/doi.org\/10.1182\/blood-2025-8230.","journal-title":"Blood"},{"key":"3557_CR76","unstructured":"U S National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06754852. Accessed 15 Jan 2026."},{"issue":"1","key":"3557_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38505-6","volume":"14","author":"CE Bravo-Iniguez","year":"2023","unstructured":"Bravo-I\u00f1iguez CE, Fritz JR, Shukla S et al. Vagus nerve stimulation primes platelets and reduces bleeding in hemophilia A male mice. Nat Commun. 2023;14(1):3122. https:\/\/doi.org\/10.1038\/s41467-023-38505-6.","journal-title":"Nat Commun"},{"issue":"6","key":"3557_CR78","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SHK.0b013e3181cc0183","volume":"33","author":"CJ Czura","year":"2010","unstructured":"Czura CJ, Schultz A, Kaipel M\u00a0et al. Vagus nerve stimulation regulates hemostasis in swine. Shock. 2010;33(6):608\u201313. https:\/\/doi.org\/10.1097\/SHK.0b013e3181cc0183.","journal-title":"Shock"},{"issue":"S1","key":"3557_CR79","doi-asserted-by":"publisher","first-page":"11731","DOI":"10.3389\/fmed.2025.1664433","volume":"144","author":"CJ Czura","year":"2024","unstructured":"Czura CJ, Weyand AC, Baldwin MK\u00a0et al. Delivering transcutaneous auricular neurostimulation to reduce heavy menstrual bleeding in von Willebrand disease patients. Blood. 2024;144(S1):11731. https:\/\/doi.org\/10.3389\/fmed.2025.1664433.","journal-title":"Blood"},{"key":"3557_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1664433","volume":"12","author":"CJ Czura","year":"2025","unstructured":"Czura CJ, Weyand AC, Baldwin MK et al. Transcutaneous auricular neurostimulation to reduce heavy menstrual bleeding in women with and without von Willebrand disease. Front Med. 2025;12:1664433. https:\/\/doi.org\/10.3389\/fmed.2025.1664433.","journal-title":"Front Med"},{"key":"3557_CR81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/hae.14655","volume":"29","author":"G Castaman","year":"2023","unstructured":"Castaman G, Katsarou O, Jansen N, Santos S, Escolar G, Berntorp E. Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: systemiatic and targeted literature reviews. Haemophilia. 2023;29:411\u201322. https:\/\/doi.org\/10.1111\/hae.14655.","journal-title":"Haemophilia"},{"issue":"3","key":"3557_CR82","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/hae.12670","volume":"21","author":"KP van Galen","year":"2015","unstructured":"van Galen KPM, Sanders YV, Vojinovic U et al. Joint bleeds in von Willebrand disease patients have significan impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015;21(3):e185\u201392. https:\/\/doi.org\/10.1111\/hae.12670.","journal-title":"Haemophilia"},{"issue":"1","key":"3557_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/aogs.12292","volume":"93","author":"TS Karlsson","year":"2014","unstructured":"Karlsson TS, Marions LB, Edlund MG. Heavy menstrual bleeding significantly affects quality of life. Acta Obstet Gynecol Scand. 2014;93(1):52\u20137. https:\/\/doi.org\/10.1111\/aogs.12292.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"3557_CR84","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3324\/haematol.2024.286014","volume":"111","author":"O Seidizadeh","year":"2026","unstructured":"Seidizadeh O, Lillicrap D. Molecular genetic testing in von Willebrand disease: past, present, and beyond. Haematologica. 2026;111(1):44\u201353. https:\/\/doi.org\/10.3324\/haematol.2024.286014.","journal-title":"Haematologica"},{"issue":"1","key":"3557_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00536-8","volume":"10","author":"O Seidizadeh","year":"2024","unstructured":"Seidizadeh O, Eikenboom JCJ, Denis CV, et al. von Willebrand disease. Nat Rev Dis Primers. 2024;10(1):51. https:\/\/doi.org\/10.1038\/s41572-024-00536-8.","journal-title":"Nat Rev Dis Primers"},{"key":"3557_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/hae.70192","author":"R Lassila","year":"2025","unstructured":"Lassila R, Atiq F, Casari C, Lavin M. Advances in von Willebrand disease. Haemophilia. 2025. https:\/\/doi.org\/10.1111\/hae.70192. (Epub 2025 Dec 11).","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"3557_CR87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-308","volume":"146","author":"A Wheeler","year":"2025","unstructured":"Wheeler A, Kshirsagar S, Giermasz A, et al. Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: results from a phase\u00a01\/2 multidose study of VGA039 in patients with von Willebrand disease. Blood. 2025;146(Supplement 1):308. https:\/\/doi.org\/10.1182\/blood-2025-308.","journal-title":"Blood"},{"key":"3557_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.07.013","author":"S Susen","year":"2025","unstructured":"Susen S, Trossa\u00ebrt M, Zilberstein M, et al. A phase\u00a01, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type\u00a02N or type\u00a03 von Willebrand disease. J Thromb Haemost. 2025. https:\/\/doi.org\/10.1016\/j.jtha.2025.07.013.","journal-title":"J Thromb Haemost"},{"issue":"735","key":"3557_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh0027","volume":"16","author":"W Strilchuk","year":"2024","unstructured":"Strilchuk W, Hur WS, Batty P, et al. Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysisin mouse and dog models of hemophilia A. Sci Transl Med. 2024;16(735):eadh0027. https:\/\/doi.org\/10.1126\/scitranslmed.adh0027.","journal-title":"Sci Transl Med"},{"issue":"S2","key":"3557_CR90","volume":"9","author":"W Strilchuk","year":"2025","unstructured":"Strilchuk W. OC 39.3 Long term use of siRNA antifibrinolytic targeting plasminogen is well tolerated in non- human primates and limits menstrual bleeding -2025 oral communications abstracts. Res Pract Thromb Haemostas. 2025;9(S2):250.","journal-title":"Res Pract Thromb Haemostas"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03557-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:14Z","timestamp":1780116674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03557-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angela C. Weyand has acted as a consultant\/participated in advisory boards for Takeda, Hemab, Sanofi, Seragene, Alnylam, and Genentech, received honoraria as a speaker for Octapharma and has received research funding from Sanofi, Hemab, Vega\/Star, Genentech, and Spark Biomedical. Mary McGrath has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}